Advertisement
| flowjo cell cycle analysis: Cell-Cycle Synchronization Zhixiang Wang, 2022-08-31 This volume covers a broad range of cell types including cultured cell lines, primary cells, and various unicellular organisms such as fission yeast, budding yeast, parasite Leishmania amazonensis, and parasite Trypanosoma brucei. The chapters in this book are organized into four parts. Part One looks at a general overview of cell cycle control and synchronization. Part Two discusses techniques to synchronize mammalian cells to various cell cycle phases including mitotic sub-phases. Part Three covers synchronization of unicellular organisms and Part Four analyzes cell cycle progression. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and thorough, Cell-Cycle Synchronization: Methods and Protocols is a valuable resource for both novice and expert scientists in this developing field. |
| flowjo cell cycle analysis: Exploiting DNA Damage Response in the Era of Precision Oncology Yitzhak Zimmer, Christian Reinhardt, Michaela Medová, 2020-12-11 Topic Editor Christian Reinhardt has received funding from companies Gilead, and lecture fees from Abbvie, Merck, and AstraZeneca. All other topic editors declare no competing interests with regards to the Research Topic subject. |
| flowjo cell cycle analysis: The Red Cell Life-Cycle From Erythropoiesis to Clearance Lars Kaestner, Anna Bogdanova, 2019-02-05 The eBook ‘The red cell life-cycle from erythropoiesis to clearance’ continues the discussion of questions like: What are the changes associated with red blood cell maturation, adulthood and senescence? What are the determinants of red blood cell life span and clearance? What are the mechanisms in control of red blood cell mass in healthy humans and patients with various forms of anaemia? Can red blood cells be 'trained' to provide the body with more oxygen during endurance exercises? What are the markers of circulating red blood cell senescence and in cells during storage and transfusion? And what can be learned from various species that developed advanced adaptations to maintain oxygen delivery under stress conditions such as exercising to the limit, diving or living in anaerobic aquatic habitats or at high altitude? Within the approximately 120 days (or 40 in a mouse, or 150-170 in a horse) life span of 'healthy' red blood cells, many cellular properties change leading to aged mixed cell populations in the circulation. Red blood cells seem to be genetically terminated by the time they become red blood cells and the contributions of this eBook increase the understanding of this process. There are surprisingly versatile remodeling processes happening during the red blood cell life span. Numerous disorders are associated with the premature onset of the 'ageing process' of red blood cells. Furthermore, in vitro ageing and/or modifications as well as the slowing down of the modifications is an important issue in transfusion medicine. Many of the molecular mechanisms behind such effects are elucidated in this eBook. |
| flowjo cell cycle analysis: Flow Cytometry with Plant Cells Jaroslav Dolezel, Johann Greilhuber, Jan Suda, 2007-06-27 Targeted at beginners as well as experienced users, this handy reference explains the benefits and uses of flow cytometery in the study of plants and their genomes. Following a brief introduction that highlights general considerations when analyzing plant cells by flow cytometric methods, the book goes on to discuss examples of application in plant genetics, genomic analysis, cell cycle analysis, marine organism analysis and breeding studies. With its list of general reading and a glossary of terms, this first reference on FCM in plants fills a real gap by providing first-hand practical hints for the growing community of plant geneticists. |
| flowjo cell cycle analysis: The Placenta, Fetomaternal Tolerance and Beyond: A Tribute to Sir Peter Medawar on the 60th Anniversary of his Nobel Prize Gabriela Barrientos, Sandra Maria Blois, Surendra Sharma, Maria Emilia Solano, Elizabeth Simpson, 2022-09-16 |
| flowjo cell cycle analysis: Flow Cytometry M. G. Ormerod, 2000-05-18 Flow cytometry is a technique widely used in biological research and in diagnostic medicine. Flow cytometers are found in most biological research institutions and most clinical laboratories in larger hospitals. |
| flowjo cell cycle analysis: Flow Cytometry in Drug Discovery and Development Virginia Litwin, Philip Marder, 2011-04-20 This book covers the unique application of flow cytometry in drug discovery and development. The first section includes two introductory chapters, one on flow cytometry and one on biomarkers, as well as a chapter on recent advances in flow cytometry. The second section focuses on the unique challenges and added benefits associated with the use of flow cytometry in the drug development process. The third section contains a single chapter presenting an in depth discussion of validation considerations and regulatory compliance issues associated with drug development. |
| flowjo cell cycle analysis: Overcoming Physiologic Barriers to Treatments for Hematologic Malignancies by Molecularly Targeting the Tumor Microenvironment Qin Wang, Lili Feng, Arif Gulfar, 2024-01-29 Hematologic malignancies (HMs) represent a group of hematologic cancers originating from bone marrow or lymphoid organs. Currently, leukaemia, lymphoma, and multiple myeloma are the most common HMs. Conventional treatments for HMs include bone marrow transplantation, radiotherapy, chemotherapy, and immunotherapy. Despite the significant achievements obtained over the past decade in the drug therapy of HMs, tumor metastasis and relapse in patients often occurred after an initial response, indicating the generation of drug resistance to current therapies. Moreover, many clinically used therapeutic drugs are often associated with dose-related side effects and a lack of specificity to tumor tissues. The tumor microenvironment (TME) in HMs consists of a complicated network of cellular interactions and signaling cross-talking within the bone marrow cavity, and it plays an essential role in the progression and metastasis of HM. Furthermore, the TME in HMs has formed physiologic barriers such as immunosuppressive microenvironment, upregulated anti-apoptotic system, drug resistance, etc. to facilitate drug resistance and relapse of HMs. It has become widely accepted that effective treatment against HMs may require targeting both the cancer cell and TME. |
| flowjo cell cycle analysis: Molecular Research of Endometrial Pathophysiology Paola Viganò, Andrea Romano, 2019-10-14 The endometrium has been the subject of intense research in a variety of clinical settings, because of its importance in the reproductive process and its role in women’s health. In the past 15 years, significant efforts have been invested in defining the molecular phenotype of the receptive phase endometrium as well as of various endometrial pathologies. Although this has generated a wealth of information on the molecular landscape of human endometrium, there is a need to complement this information in light of the novel methodologies and innovative technical approaches. The focus of this International Journal of Molecular Sciences Special Issue is on molecular and cellular mechanisms of endometrium and endometrium-related disorders. The progress made in the molecular actions of steroids, in the metabolism of steroids and intracrinology, in endometrial intracellular pathways, in stem cells biology, as well as in the molecular alterations underlying endometrium-related pathologies has been the focus of the reviews and papers included.] |
| flowjo cell cycle analysis: Transcription Regulation - Brain Development and Homeostasis - A Finely Tuned and Orchestrated Scenario in Physiology and Pathology, Volume II Estela Maris Muñoz, Veronica Martinez Cerdeño, 2023-10-03 A finely tuned regulation of gene expression is essential for shaping the nervous system and for maintaining its homeostasis throughout life. Disruptions in gene regulation can impact brain development and physiology in ways that contribute to diverse pathologies. The master orchestrators of gene activity in the nucleus are transcription factors, proteins that recognize and bind to specific DNA motifs in regulatory regions and drive changes in gene expression. Transcription factors act with the help of other co-factor proteins, including components of the Mediator complex, histone modifying enzymes, chromatin modelers, and DNA methylases. In addition, transcription factor activity in the nervous system can be modulated by extracellular signals, including growth factors, hormones, neuropeptides and neurotransmitters that activate specific receptors and intracellular transduction pathways. An in-depth understanding of the mechanisms of transcription regulation is needed in order to better describe how each element, from genes to cells, defines and maintains identities and functionalities in the healthy and diseased brain. This Research Topic is oriented to developing an integrative view about transcription regulation within the nervous system, focusing on developmental and homeostatic processes, dysregulation in functionality and expression levels and consequent associated pathologies such as neurodevelopmental disorders, brain tumors, and neurodegenerative diseases. Transcription regulation investigations will specifically focus on transcription factors that belong to the bHLH (e.g. NeuroD), homeobox (e.g. Islet, Pax, Rax, and Lhx) and CREB families, and on their roles over defined nervous system areas: cerebral cortex, thalamic and hypothalamic areas, interacting with the developing brain. |
| flowjo cell cycle analysis: Targeting DNA damage response to enhance antitumor innate immunity in radiotherapy Qiang Zhang, Rachel Evans, Marco Tigano, 2023-09-08 |
| flowjo cell cycle analysis: Understanding mitochondrial dynamics and metabolic plasticity in cancer stem cells: Recent advances in cancer treatment and potential therapeutic approaches Pramod Darvin, Varun Sasidharan Nair, 2023-06-02 |
| flowjo cell cycle analysis: Fibroblast Growth Factors Xiaokun Li, 2023-11-16 Fibroblast Growth Factors, Second Edition systematically introduces readers to FGF in the fields of injury repair and regeneration, endocrinology and metabolism, structure and modification, pharmaceutics, pharmacology, FGF/FGFR inhibitor, engineering and new drug development. Fibroblast growth factors (FGFs) are secreted protein ligands that act in a paracrine or endocrine fashion to carry out their pleiotropic functions in development, tissue homeostasis and metabolism. This book covers the work from Li's team from 2013 to 2018 and will be a primer for scientists, particularly young students entering the FGFs field with an eye on basic research and application. - Contains approximately 90% new material on topics covered - Includes information on breakthrough discoveries which have been made since the publication of the first edition - Introduces detailed research methods and technologies of FGFs so the book can be used as a toolbox by the user - Includes comprehensive and systematic research and industry application |
| flowjo cell cycle analysis: The Role of Iron in Cancer Progression Maryam Mehrpour, Ahmed Hamaï, Chang Gong, 2022-11-04 |
| flowjo cell cycle analysis: From Chronic Inflammation to Cancer: How Far Can Immunotherapy Go? Zhaogang Yang, Xuefeng Li, Lesheng Teng, 2022-02-18 |
| flowjo cell cycle analysis: Cellular Senescence and Aging , 2024-01-30 Cellular Senescence and Aging, Volume 181 in the Methods in Cell Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on topics such as assessing polyglutamine tract aggregation in the nematode Caenorhabditis elegans, Generation of glial cell-derived neurotrophic factor (gdnf) morphants in zebrafish larvae by cerebroventricular microinjection of vivo morpholino, Methods for detection of mitochondrial reactive oxygen species in senescent cells, Assessment of cell cycle progression and mitotic slippage by videomicroscopy, The original colorimetric method to detect cellular senescence, and more.Additional sections cover Assessing microbiota composition in the context of aging, Assessing chronological aging in Saccharomyces cerevisiae, Image processing and supervised machine learning for retinal microglia characterization in senescence, Measuring telomerase activity using TRAP assays, High throughput assessment of cellular senescence, Detection of radiation-induced senescence by the Debacq-Chainiaux protocol: Improvements and upgrade in the detection of positive events, Dynamic and scalable assessment of the senescence-associated secretory phenotype (SASP), Flow cytometry-assisted quantification of cell cycle arrest in cancer cells treated with CDK4/6 inhibitors, and more. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in the Methods in Cell Biology series - Updated release includes the latest information on Cellular Senescence and Aging |
| flowjo cell cycle analysis: Intraoperative Flow Cytometry Georgios Alexiou, Georgios Vartholomatos, 2023-07-26 This book describes intraoperative flow cytometry in solid tumours. Intraoperative flow cytometry is an innovative technique for assessing tumour margins and grade of malignancy intraoperatively. The authors have been working on this procedure for more than 14 years and have introduced it in the surgery of intracranial tumours, breast cancer, liver cancer and head and neck neoplasms, as described in the book. A detailed description of the main pathological findings will be followed by an explanation of the intraoperative flow cytometry’s role. In each chapter, information will be provided to stimulate further research on this topic. The book will also include new topics that have not been published till now. The book is aimed at neurosurgeons, general surgeons, ENT specialists, breast surgeons, radiologists, pathologists, oncologists, biologists, biochemists and scientists working with on flow cytometry. |
| flowjo cell cycle analysis: Cell Lineage Choice During Haematopoiesis: A Commemorative Issue in Honor of Professor Antonius Rolink Geoffrey Brown, Rhodri Ceredig, 2018-11-13 This book is a printed edition of the Special Issue Cell Lineage Choice During Haematopoiesis: A Commemorative Issue in Honor of Professor Antonius Rolink that was published in IJMS. |
| flowjo cell cycle analysis: AACR 2019 Proceedings: Abstracts 1-2748 American Association for Cancer Research, 2019-03-08 American Association for Cancer Research 2019 Proceedings: Abstracts 1-2748 - Part A |
| flowjo cell cycle analysis: Targeted Cancer Therapies, From Small Molecules to Antibodies Zhe-Sheng Chen, Jian-ye Zhang, Yunkai Zhang, Yan-yan Yan, 2020-07-22 |
| flowjo cell cycle analysis: Physiology of Myelin Forming Cells, from Myelination to Neural Modulators Mauricio Antonio Retamal, Fernando C. Ortiz, Marion Baraban, 2020-01-16 |
| flowjo cell cycle analysis: Molecular Markers and Targeted Therapy for Hepatobiliary Tumors, volume I.A Yunfei Xu, Zongli Zhang, Hongda Liu , Xuesong Gu, 2024-07-26 Hepatobiliary tumor, mainly including hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer, is a group of highly aggressive malignancies. Hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer have different biological characters, histopathological traits, and treatment strategies, but have similar clinical features such as silent early symptom and extremely poor prognosis. The diagnostic, predictive or prognostic tumor biomarkers of hepatobiliary cancers are in unmet need. In contrast to the poor outcome, the treatment options to hepatobiliary cancers are very limited. It is still controversial about the effects of chemotherapy and radiotherapy of hepatobiliary cancer. FDA-approved targeted drugs are only Sorafenib and Lenvatinib for hepatocellular carcinoma, and Pemigatinib for cholangiocarcinoma. Unfortunately, these drugs are only effective for 5%-30% patients. Therefore, more attention should be called upon on investigating effective biomarkers and drug targets, stratifying high-risk patients, guiding precise treatments, and developing therapeutic strategies for hepatobiliary cancers. This Research Topic aims at discussing the current knowledge and proceedings of diagnostic, predictive and prognostic tumor biomarkers in hepatobiliary cancer, and presenting the recent advances on new drug targets and potential targeted therapies of hepatobiliary cancer. We welcome submissions of Review, Mini-Review, Clinical Trial and Original Research articles covering, but not limited to, the following topics: 1. new diagnostic/prognostic factors, biomarkers and/or risk factors in hepatobiliary tumors 2. new drug targets, and oncogenic or tumor suppressive molecular mechanism of the novel targets 3. new intervention or targeted therapy in hepatobiliary tumors 4. new findings of bioinformatics or high-throughput methods such as mass spectrometry and genome-wide association studies or which may help screen the potential biomarkers of hepatobiliary tumors 5. clinical studies such as cohort study or RCT to identify new risks or treatment therapies in hepatobiliary tumors 6. basic, pharmacological, preclinical or clinical study of potential drugs targeting hepatobiliary tumors Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic. |
| flowjo cell cycle analysis: Enzyme or Whole Cell Immobilization for Efficient Biocatalysis: Focusing on Novel Supporting Platforms and Immobilization Techniques Wen-Yong Lou, Jun Ge, Changzhu Wu, Jesús Fernández Lucas, 2021-04-21 |
| flowjo cell cycle analysis: World Congress on Medical Physics and Biomedical Engineering September 7 - 12, 2009 Munich, Germany Olaf Dössel, Wolfgang C. Schlegel, 2010-01-01 Present Your Research to the World! The World Congress 2009 on Medical Physics and Biomedical Engineering – the triennial scientific meeting of the IUPESM - is the world’s leading forum for presenting the results of current scientific work in health-related physics and technologies to an international audience. With more than 2,800 presentations it will be the biggest conference in the fields of Medical Physics and Biomedical Engineering in 2009! Medical physics, biomedical engineering and bioengineering have been driving forces of innovation and progress in medicine and healthcare over the past two decades. As new key technologies arise with significant potential to open new options in diagnostics and therapeutics, it is a multidisciplinary task to evaluate their benefit for medicine and healthcare with respect to the quality of performance and therapeutic output. Covering key aspects such as information and communication technologies, micro- and nanosystems, optics and biotechnology, the congress will serve as an inter- and multidisciplinary platform that brings together people from basic research, R&D, industry and medical application to discuss these issues. As a major event for science, medicine and technology the congress provides a comprehensive overview and in–depth, first-hand information on new developments, advanced technologies and current and future applications. With this Final Program we would like to give you an overview of the dimension of the congress and invite you to join us in Munich! Olaf Dössel Congress President Wolfgang C. |
| flowjo cell cycle analysis: Multi-targeted Natural Products as Cancer Therapeutics: Challenges and Opportunities, Volume I, 2nd edition Jiang-Jiang Qin, Wei-Dong Zhang, Huizi Jin, Sanjay K. Srivastava, 2024-01-11 This Research Topic is part of a series with: Multi-targeted Natural Products as Cancer Therapeutics: Challenges and Opportunities, Volume II Cancer remains a leading cause of disease-related deaths worldwide, despite recent advances in our understanding of cancer initiation, progression, and metastasis. Chemotherapy and radiotherapy have been used as standard non-surgical treatments of human cancer for decades, however, the survival rates of patients with cancer, especially those with advanced diseases are still very low due to the high toxicities of these treatments as well as the severe side effects. This fact has motivated researchers to discover new cancer therapeutics with minimum side effects, which intensively promotes the rapid development of single specific molecule-targeted therapies (SSMTT). Many efforts have been made in world-wide cancer drug discovery research and several single molecule-targeted therapies have been successfully developed. Unfortunately, most of the investments failed because cancer is a genetic disease and always harbors multiple alternations of molecules or genes at the genomic, genetic and epigenetic levels. The inhibition of a single molecule or signaling pathway by SSMTT frequently results in a hyperactive compensation of other cancer-related molecules and signaling pathways as well as the subsequent development of drug resistance. Therefore, identifying multi-targeted therapies, i.e. drugs that are able to target multiple cancer-related genes, proteins, or signaling pathways is a more promising way to success in developing new cancer therapeutics. Natural products, especially those from traditional Chinese medicine and folk remedies in other countries are an extraordinarily important source for new drug discovery over the past decades. Of note, many natural products have often been demonstrated to target several crucial genes or proteins in cancer-related signaling networks and exert synergistic effects. For example, Japonicone A, a dimeric sesquiterpenoid from the medicinal plant Inula japonica, has been found to inhibit tumor growth and metastasis by dually targeting the TNF-α/NF-κB and p53/MDM2 signaling pathways. Traditionally, researchers have believed that the multi-targeting mechanisms of natural products have limited their use in cancer treatment due to the low specificity and potential side effects. The growing interest in developing multi-targeted cancer therapies may provide another golden opportunity to develop natural products as new cancer therapeutics. Nevertheless, critical investigations for a comprehensive understanding of the molecular mechanisms of natural products also mean more challenges. Our long-term goals are to fully understand the molecular targets and mechanisms of action of anticancer natural products and develop them as novel cancer preventive and therapeutic agents. The specific goal of this Research Topic is to bring together the recent findings of newly identified anticancer natural products, especially those with multiple molecular targets. Papers (Original Research articles or Reviews) which discuss the in vitro and in vivo efficacy and pharmacological and toxicological properties of natural products are also welcome to be submitted. Guidelines for the conception and review of submissions As many anticancer drugs working as cytotoxic compounds have non-selective effects annihilating their potential therapeutic benefits, manuscripts are advised to provide evidence of a significant selectivity towards cancer cells (vs. healthy cells). Specifically, if the studied anticancer drug or modality does not target an oncogenic pathway, the authors should make every effort possible to prove that the cytotoxic or cytostatic effects they have identified exhibit selectivity for cancer cells (ideally 1 log difference in EC50 or IC50) vs. non-malignant cells (eg, fibroblasts or primary culture of cells). The authors should also demonstrate the applicability of their anticancer modalities on a minimum of two well-authenticated cancer cell lines (ideally originating from distinct organs/tissues). For manuscripts dealing with plant extracts or other natural substances/compounds, the composition and the stability of the study material must be described in sufficient detail. In particular, for extracts, chromatograms with characterization of the dominating compound(s) are requested. The level of purity must be proven and included. Please refer to the Four Pillars of Best Practice in Ethnopharmacology, a subset of which concerning general standards in natural product research are applied to all such studies in all sections of Frontiers in Pharmacology. |
| flowjo cell cycle analysis: Innate Immunity Pathways in Autoimmune Diseases Moncef Zouali, Antonio La Cava, 2019-12-10 |
| flowjo cell cycle analysis: Current Protocols on CD-ROM. , 1997 |
| flowjo cell cycle analysis: Frontiers in Oncology: Quarterly Highlights. Quarter 1 2019 Giuseppe Giaccone, 2019-07-01 Foreword from the Field Chief Editor, Giuseppe Giaccone Once again Frontiers in Oncology has started the year on a positive note, breaking previous records for submissions and publications, as well as the number of Research Topic article collections posted. The journal continues to grow in size, adding an 18th section focusing on Cancer Metabolism, led by Michael Lisanti and Ubaldo Martinez-Outschoorn, and has brought on a total of five new Chief Editors. Here, introducing Frontiers in Oncology: Quarterly Highlights, we feature a collection of carefully selected articles published during the first quarter of 2019 across the different sections. With a record number of papers to choose from, the papers enclosed in this Special Edition highlight some of the recent advances across the different disciplines. With an array of papers looking at everything from translational research to association studies and clinical trial results, Frontiers in Oncology continues to publish high-quality research from researchers around the world. Many of the recently posted Research Topics in the journal focus on early diagnosis and prevention, as well as the importance of survivorship studies and outcomes of cancer treatment. Consideration of such aspects of cancer research and treatment is pivotal in the global effort towards increased survival rates and improved quality of life. With ASCO 2019 marking the end of Q1 and the transition into Q2, the journal looks forward to the rest of the year, and continuing to play an active role in the research community. Giuseppe Giaccone |
| flowjo cell cycle analysis: Mesoporous Materials for Drug Delivery and Theranostics Valentina Cauda, Giancarlo Canavese, 2020-12-17 Mesoporous materials are capturing great interest thanks to their exceptional surface area, uniform and tunable pore size, ease surface functionalization, thus enabling broad series of intervention in the field of nanomedicine. Since many years, these aspects foster a deep investigation on mesoporous nanoparticles, to design and fabricate biocompatible, smart and stimuli-responsive nanotools for controlled drug- or gene-delivery, theranostics applications, in particular for cancer therapy, and tissue engineering. This Book is thus dedicated to the most recent advances in the field, collecting research papers and reviews. It spans from the synthesis and characterization of the mesoporous material, especially those made of silica, silicon and bioactive glasses, to their functionalization with smart gate-keepers, reporter molecules or targeting ligands, up to their in-vitro applications in the nanomedicine field. |
| flowjo cell cycle analysis: Anticancer Agents Qiao-Hong Chen, 2021-03-02 This book is a printed edition of the Special Issue entitled “Anticancer Agents: Design, Synthesis and Evaluation” that was published in Molecules. Two review articles and thirty research papers are included in the Special Issue. Three second-generation androgen receptor antagonists that have been approved by the U.S. FDA for the treatment of prostate cancer have been reviewed. Identification of mimics of protein partners as protein-protein interaction inhibitors via virtual screening has been summarized and discussed. Anticancer agents targeting various protein targets, including IGF-1R, Src, protein kinase, aromatase, HDAC, PARP, Toll-Like receptor, c-Met, PI3Kdelta, topoisomerase II, p53, and indoleamine 2,3-dioxygenase, have been explored. The analogs of three well-known tubulin-interacting natural products, paclitaxel, zampanolide, and colchicine, have been designed, synthesized, and evaluated. Several anticancer agents representing diverse chemical scaffolds were assessed in different kinds of cancer cell models. The capability of some anticancer agents to overcome the resistance to currently available drugs was also studied. In addition to looking into the in vitro ability of the anticancer agents to inhibit cancer cell proliferation, apoptosis, and cell cycle, in vivo antitumor efficacy in animal models and DFT were also investigated in some papers. |
| flowjo cell cycle analysis: The Journal of Immunology , 2008 |
| flowjo cell cycle analysis: Regulation of Immune Function by the Lymphatic Vasculature Beth A. Jirón Tamburini, Amanda W. Lund, Timothy P. Padera, 2020-01-22 |
| flowjo cell cycle analysis: Metabolic Plasticity of Cancer Tuuli Käämbre, Rafael Moreno-Sánchez, Sara Rodriguez-Enriquez, 2020-12-24 This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact. |
| flowjo cell cycle analysis: Leishmaniasis: Control and Elimination Om Prakash Singh, Rajiv Kumar, Christy Petersen, Shyam Sundar, Epke Le Rutte, 2022-02-07 |
| flowjo cell cycle analysis: Combating Cancer with Natural Products: What Would Non-Coding RNAs Bring? Yongye Huang, Yue Hou, Peng Qu, Yong Cai, 2021-11-05 |
| flowjo cell cycle analysis: DNA Repair, Part B , 2011-09-21 This volume emphasizes the intracellular consequences of DNA damage, describing procedures for analysis of checkpoint responses, DNA repair in vivo, replication fork encounter of DNA damage, as well as biological methods for analysis of mutation production and chromosome rearrangements. It also describes molecular methods for analysis of a number of genome maintenance activities including DNA ligases, helicases, and single-strand binding proteins.*Part B of a 2-part series*Addresses DNA maintenance enzymes*Discusses damage signaling*Presents In vivo analysis of DNA repair*Covers mutation and chromosome rearrangements |
| flowjo cell cycle analysis: Emerging Molecular Mechanisms of Cell Cycle Regulation in Cancer: Functions and Potential Applications Yueming Sun, Junhui Hu, Mingyan Zhu, 2022-03-07 |
| flowjo cell cycle analysis: Regulatory RNAs in the Nucleus Xiao Li, Liang Chen, Wenbo Li, Yuanchao Xue, Bing Zhou, 2021-11-30 Topic Editors Xiao Li, Bing Zhou, and Wenbo Li hold patents related to the Research Topic subject. All other Topic Editors declare no competing interests. |
| flowjo cell cycle analysis: Handbook Of Immunological Properties Of Engineered Nanomaterials (Second Edition) (In 3 Volumes) Marina A Dobrovolskaia, Scott E Mcneil, 2016-01-28 This unique book provides comprehensive overview of the field of immunology related to engineered nanomaterials used for biomedical applications. It contains literature review, case studies and protocols. The book can serve as a source of information about nanoimmunotoxicology for both junior scientists and experts in the field. The authors have more than 10 years of experience with preclinical characterization of engineered nanomaterials used for medical applications, and they share their experience with the readers. In addition, the international team of experts in the field provides the opinion and share the expertise on individual topics related to nanoparticle physicochemical characterization, hematocompatibility, and effects on the immune cell function . The second edition contains updated chapters from the first edition plus new chapters covering areas of tumor immunology, nanoparticle interaction with lymphatic system, mathematical modeling of protein corona, utilization of nanoparticles for the delivery of antiviral drugs, extensive analysis of nanoparticle anti-inflammatory and immunosuppressive properties, novel ways of protecting therapeutic nanoparticles from the immune recognition, as well as case studies regarding nanoparticle sterilization, complement activation, protein binding and immunotherapy of cancer. The second edition comes in 3 volumes. Volume 1 is focused on nanoparticle characterization, sterility and sterilization, pyrogen contamination and depyrigenation. It also contains overview of regulatory guidelines, protocols for in vitro and in vivo immunotoxicity studies, and correlation between in vitro and in vivo immunoassays. Volume 2 is focused on hematocompatibility of nanomaterials. It provides comprehensive review and protocols for investigating nanoparticle interaction with erythrocytes, platelets, endothelial cells, plasma coagulation factors and plasma proteins forming so called 'corona' around nanoparticles. Volume 3 is dedicated to nanoparticle interaction with and effects on the immune cell function. It also contains examples of nanoparticle use for delivery of antiviral and anti-inflammatory drugs. |
| flowjo cell cycle analysis: Molecular Genetics and Emerging Therapies for Epithelial Ovarian Cancer: Basic Research and Clinical Perspectives Stergios Boussios, Eleftherios Pierre Samartzis, Nicholas Pavlidis, J. Alejandro Perez-Fidalgo, 2023-11-06 Epithelial ovarian cancer (EOC) is the most lethal gynecological disorder due to a lack of effective early detection strategies. Worldwide, approximately 230,000 women are diagnosed annually, whereas 150,000 die. It represents the seventh most commonly diagnosed cancer among women in the world with 5-year survival rate of 46%. More than one-fifth of EOC have been related to hereditary conditions. Considerable efforts have been made to implement screening of the general population to diagnose EOC early; nevertheless, this has been ineffective and there is no approved strategy. Nowadays, new approaches for early diagnosis and prevention based on molecular genomics are in development. Whole genome sequencing has established the potency of the somatic genome, characterised with diverse DNA repair deficiencies that can be used to stratify EOCs into distinct biological groups with predictive signatures of resistance or relapse. The incorporation of next-generation sequencing (NGS) into clinical practice remains challenging for two reasons. Firstly, the EOC risk is not clear for some of the included genes and secondly, the variant of uncertain significance rates increase as more genes are analyzed. Finally, beyond germline pathogenic variants, somatic mutations may also affect therapeutic choices, and as such upfront tumor sequencing may be equally important to NGS, particularly as we continue to challenge treatment paradigms in the first‐line management of EOC. |
Home | FlowJo, LLC
FlowJo, your flow cytometry data analysis software, is dedicated to helping you speed up routine phenotyping, elevate your immunology research, and efficiently transform data into …
FlowJo 11 - Download | FlowJo, LLC
Updating to the latest version is FREE and EASY for current FlowJo v10 customers with a FlowJo Portal License. Simply download the latest version of FlowJo v11 below and sign in with your …
FlowJo 11 Overview | FlowJo, LLC
What's FlowJo? With a new intuitive interface, rich analysis tools, and easy-to-use features for flow cytometry data analysis, FlowJo™ v11 Software introduces new innovation for advanced …
FlowJo 11 - Free Trial | FlowJo, LLC
FlowJo™ v11 30-day Free Trial. With an active FlowJo Portal license, you can use both FlowJo™ v10 and v11. If you don’t have a FlowJo Portal license, then create an account and try out v11 …
Learn FlowJo Now! - FlowJo Documentation
FlowJo is a highly intuitive program for cytometric data analysis, and getting started is easy! A little time spent learning about the following components will help you save precious time and …
Learn - FlowJo University | FlowJo, LLC
FlowJo™ is the leading analysis platform for single-cell flow and mass cytometry analysis. Take your data to the next level with the latest tools in FlowJo v10.
Getting Started and FlowJo Licensing Information
Obtaining a FlowJo License. You have downloaded the full version of FlowJo. However, until a portal license, serial number or dongle is provided, FlowJo will only load specially enabled …
Learn - Help-Documentation | FlowJo, LLC
FlowJo™ is the leading analysis platform for single-cell flow and mass cytometry analysis. Take your data to the next level with the latest tools in FlowJo™ v10 Software. Read Documentation
FlowJo 11 - Learn | FlowJo, LLC
Get a look at FlowJo™ Software Version 11! In this webinar we will discuss the philosophy of this version, new features at a high level, and then demonstrate a full workflow to show the …
FlowJo 11 - Early Access | FlowJo, LLC
FlowJo™ Software v11 Early Access Versions. No Early Access builds are available at this time. Please contact john.flowjo@bd.com about future participation in the Early Access program.
Home | FlowJo, LLC
FlowJo, your flow cytometry data analysis software, is dedicated to helping you speed up routine phenotyping, elevate your immunology research, and efficiently transform data into …
FlowJo 11 - Download | FlowJo, LLC
Updating to the latest version is FREE and EASY for current FlowJo v10 customers with a FlowJo Portal License. Simply download the latest version of FlowJo v11 below and sign in with your …
FlowJo 11 Overview | FlowJo, LLC
What's FlowJo? With a new intuitive interface, rich analysis tools, and easy-to-use features for flow cytometry data analysis, FlowJo™ v11 Software introduces new innovation for advanced …
FlowJo 11 - Free Trial | FlowJo, LLC
FlowJo™ v11 30-day Free Trial. With an active FlowJo Portal license, you can use both FlowJo™ v10 and v11. If you don’t have a FlowJo Portal license, then create an account and try out v11 …
Learn FlowJo Now! - FlowJo Documentation
FlowJo is a highly intuitive program for cytometric data analysis, and getting started is easy! A little time spent learning about the following components will help you save precious time and …
Learn - FlowJo University | FlowJo, LLC
FlowJo™ is the leading analysis platform for single-cell flow and mass cytometry analysis. Take your data to the next level with the latest tools in FlowJo v10.
Getting Started and FlowJo Licensing Information
Obtaining a FlowJo License. You have downloaded the full version of FlowJo. However, until a portal license, serial number or dongle is provided, FlowJo will only load specially enabled …
Learn - Help-Documentation | FlowJo, LLC
FlowJo™ is the leading analysis platform for single-cell flow and mass cytometry analysis. Take your data to the next level with the latest tools in FlowJo™ v10 Software. Read Documentation
FlowJo 11 - Learn | FlowJo, LLC
Get a look at FlowJo™ Software Version 11! In this webinar we will discuss the philosophy of this version, new features at a high level, and then demonstrate a full workflow to show the …
FlowJo 11 - Early Access | FlowJo, LLC
FlowJo™ Software v11 Early Access Versions. No Early Access builds are available at this time. Please contact john.flowjo@bd.com about future participation in the Early Access program.
